HIF-1α Confers Aggressive Malignant Traits on Human Tumor Cells Independent of Its Canonical Transcriptional Function

被引:39
作者
Yoo, Young-Gun [1 ]
Christensen, Jared [1 ]
Huang, L. Eric [1 ,2 ]
机构
[1] Univ Utah, Dept Neurosurg, Salt Lake City, UT 84132 USA
[2] Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84132 USA
关键词
HYPOXIA-INDUCIBLE FACTOR; HIPPEL-LINDAU PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; C-MYC; E-CADHERIN; HIF-ALPHA; GENETIC INSTABILITY; PROLINE HYDROXYLATION; PROLYL HYDROXYLATION; EPITHELIAL PHENOTYPE;
D O I
10.1158/0008-5472.CAN-10-2360
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hypoxia is known to favor tumor survival and progression. Numerous studies have shown that hypoxia-inducible factor 1 alpha (HIF-1 alpha), an oxygen-sensitive transcription factor, is overexpressed in various types of human cancers and upregulates a battery of hypoxia-responsive genes for the growth and survival of cancer cells. Although tumor progression involves the acquisition of genetic and/or epigenetic changes that confer additional malignant traits, the underlying mechanisms of these changes remain obscure. We recently identified an alternative mechanism of HIF-1 alpha function by which HIF-1 alpha suppresses DNA repair by counteracting c-Myc transcriptional activity that maintains gene expression. Here, we show that this HIF-alpha-c-Myc pathway plays an essential role in mediating hypoxic effects on malignant progression via genetic alterations, resulting in the formation of malignant tumors with aggressive local invasion and epithelial-mesenchymal transition. We show an absolute requirement of the HIF-alpha-c-Myc pathway for malignant progression, whereas the canonical transcription function of HIF-1 alpha alone is insufficient and seemingly dispensable. This study indicates that HIF-1 alpha induction of genetic alteration is the underlying cause of tumor progression, especially by the hypoxic microenvironment. Cancer Res; 71(4); 1244-52. (C)2011 AACR.
引用
收藏
页码:1244 / 1252
页数:9
相关论文
共 50 条
[1]   HYPOXIA AND METABOLISM SERIES - TIMELINE The impact of O2 availability on human cancer [J].
Bertout, Jessica A. ;
Patel, Shetal A. ;
Simon, M. Celeste .
NATURE REVIEWS CANCER, 2008, 8 (12) :967-975
[2]   Hypoxia, DNA repair and genetic instability [J].
Bristow, Robert G. ;
Hill, Richard P. .
NATURE REVIEWS CANCER, 2008, 8 (03) :180-192
[3]   Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies [J].
Brown, JM .
MOLECULAR MEDICINE TODAY, 2000, 6 (04) :157-162
[4]   The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion [J].
Comijn, J ;
Berx, G ;
Vermassen, P ;
Verschueren, K ;
van Grunsven, L ;
Bruyneel, E ;
Mareel, M ;
Huylebroeck, D ;
van Roy, F .
MOLECULAR CELL, 2001, 7 (06) :1267-1278
[5]   WWOX: Its Genomics, Partners, and Functions [J].
Del Mare, Sara ;
Salah, Zaidoun ;
Aqeilan, Rami I. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2009, 108 (04) :737-745
[6]   Chromosome fragile sites [J].
Durkin, Sandra G. ;
Glover, Thomas W. .
ANNUAL REVIEW OF GENETICS, 2007, 41 :169-192
[7]   RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis (Retracted article. See vol. 579, pg. 456, 2020) [J].
Erler, JT ;
Bennewith, KL ;
Nicolau, M ;
Dornhöfer, N ;
Kong, C ;
Le, QT ;
Chi, JTA ;
Jeffrey, SS ;
Giaccia, AJ .
NATURE, 2006, 440 (7088) :1222-1226
[8]   Regulation of E-cadherin expression by VHL and hypoxia-inducible factor [J].
Esteban, MA ;
Tran, MGB ;
Harten, SK ;
Hill, P ;
Castellanos, MC ;
Chandra, A ;
Raval, R ;
O'Brien, TS ;
Maxwell, PH .
CANCER RESEARCH, 2006, 66 (07) :3567-3575
[9]   VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail [J].
Evans, Andrew J. ;
Russell, Ryan C. ;
Roche, Olga ;
Burry, T. Nadine ;
Fish, Jason E. ;
Chow, Vinca W. K. ;
Kim, William Y. ;
Saravanan, Arthy ;
Maynard, Mindy A. ;
Gervais, Michelle L. ;
Sufan, Roxana I. ;
Roberts, Andrew M. ;
Wilson, Leigh A. ;
Betten, Mark ;
Vandewalle, Cindy ;
Berx, Geert ;
Marsden, Philip A. ;
Irwin, Meredith S. ;
Teh, Bin T. ;
Jewett, Michael A. S. ;
Ohh, Michael .
MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (01) :157-169
[10]   HIF-1 as a target for drug development [J].
Giaccia, A ;
Siim, BG ;
Johnson, RS .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (10) :803-811